First bullet, Low-dose oral minoxidil for hair loss has a good safety profile. Only 1.7% of patients required discontinuation of the drug due to adverse effects. Second bullet, Although infrequent, dermatologists should be aware of the potential systemic adverse effects…

This network meta-analysis of moderate-to-severe psoriasis treatments found that anti-IL-23 agents were associated with low safety event rates and that risankizumab had the most favorable long-term benefit-risk profile. The comparative safety data for psoriasis treatments can inform treatment decision-making in…